Educational analysis only, not insurance or medical advice; all Medicare figures cited are official 2026 amounts published by the Centers for Medicare & Medicaid Services.
TL;DR — Quick Verdict
- Two switching windows exist, and they do different jobs: the Annual Enrollment Period (October 15–December 7) is open to everyone, while the Medicare Advantage Open Enrollment Period (January 1–March 31) permits current Advantage enrollees exactly one change.
- Switching out of Medicare Advantage after March 31 without a Special Enrollment Period generally means waiting until the next AEP — a delay that can expose a high-utilizer to a full year of an unfavorable out-of-pocket structure.
- The standard Part B premium is $202.90 per month in 2026 with a $283 annual deductible; these apply regardless of which switch you make.
- The 12-month Medigap trial right is the single most valuable switching protection in Medicare, and it fires only once — for a first-time Advantage enrollment.
- Dropping Advantage without adding standalone Part D leaves you with no drug coverage and exposure well past the $2,100 Part D out-of-pocket cap that would otherwise apply.
- Recommendation: run your switch decision against your drug list and your Medigap underwriting status before the March 31 deadline, not after.
Roughly 8% of Medicare beneficiaries pay income-adjusted premiums, according to the Centers for Medicare & Medicaid Services — and many of them discover that fact only after a plan switch has already locked in. Switching Medicare coverage looks like a simple online transaction. It is not. The federal rules governing when you may switch, what you may switch to, and whether an insurer such as UnitedHealthcare, Humana, or Aetna can medically underwrite your application are three separate systems that interact in ways that punish the unprepared.
This analysis breaks down each switching window by exact date and eligible action, prices the 2026 cost structure you inherit under each path using official CMS figures, models a real switching scenario with dollar math, and identifies the five errors that cost beneficiaries the most money. The single most expensive mistake is not choosing the wrong plan. It is choosing the right plan at a moment when the law no longer allows you to buy it.
The Four Switching Windows and What Each One Actually Permits
Confusion between enrollment periods drives more bad Medicare outcomes than any pricing error. Each window has a distinct audience, a distinct set of permitted actions, and a distinct effective date.
The Annual Enrollment Period runs October 15 through December 7, and it is the only universal window. Anyone with Medicare may use it, changes take effect January 1, and — critically — you may change your mind repeatedly within the window, with the last submitted election controlling. The Medicare Advantage Open Enrollment Period is narrower by design. It runs January 1 through March 31 and applies only to people already enrolled in an Advantage plan. Medicare Rights Center notes that Medical Savings Account enrollees, cost plan members, and PACE participants are excluded. You get one change, and it takes effect the first day of the following month — a February election starts March 1.
Source: Centers for Medicare & Medicaid Services enrollment period rules, 2026 (verify at cms.gov); Medicare Rights Center.
Notice the trap embedded in the January window. Someone on Original Medicare who wants to join an Advantage plan cannot do so between January and March. That door only opens in the fall. The January window is an exit, not an entrance.
The 2026 Cost Structure You Inherit With Each Switch
Every switching decision lands you on one of two cost architectures, and both are anchored by figures the federal government sets rather than the insurer. CMS set the standard Part B premium at $202.90 monthly for 2026, an increase of $17.90 — roughly 9.7% — over the 2025 rate of $185.00. That premium follows you into Advantage, out of Advantage, and through every switch you make. Understanding Part B premium and IRMAA tiers matters before you model anything else, because higher earners pay materially more.
Source: Centers for Medicare & Medicaid Services, 2026 Medicare Parts A & B Premiums and Deductibles, and 2026 Part D parameters (verify at cms.gov).
Original Medicare has no annual out-of-pocket ceiling on Part A and Part B services, which is the entire reason Medigap exists. Advantage plans do carry a ceiling, and the design of that Advantage out-of-pocket maximum coverage varies sharply between carriers. That single structural difference — capped versus uncapped — should drive the switch more than any premium comparison.
The 12-Month Trial Right: How the Most Valuable Switching Protection Works
Federal law grants one narrow escape hatch that most beneficiaries never learn about until it has expired. CMS guidance describes it as a trial right, and it applies in two situations: you joined an Advantage plan when first eligible for Medicare at 65, or you were in Original Medicare with a Medigap policy, dropped that policy, and enrolled in Advantage for the first time.
Under either scenario, you may disenroll during the first 12 months, return to Original Medicare, and buy a Medigap policy on a guaranteed-issue basis — no health questions, no medical underwriting, no premium loading for pre-existing conditions. The application window is generally 63 days from the date Advantage coverage ends, and it can open as early as 60 days before that date.
Two constraints matter enormously. First, the phrase “for the first time” is literal. Someone who has cycled through Advantage previously does not get a fresh trial right on a later enrollment. Second, if you dropped a specific Medigap policy to try Advantage, the guarantee is to repurchase that same policy from that same insurer, provided the insurer still sells it. When it does not, guaranteed-issue rights extend to a defined subset of standardized plans. People who became Medicare-eligible on or after January 1, 2020 cannot purchase Plan C or Plan F, which is why the Plan G vs Plan N cost comparison has become the practical decision for most new switchers.
Outside a trial right or another guaranteed-issue event, most states permit Medigap insurers to underwrite. A beneficiary with a recent cardiac event, an active cancer diagnosis, or insulin-dependent diabetes may simply be declined. The switch becomes one-directional — an outcome that also depends on Medigap premium rating methods compared across attained-age, issue-age, and community-rated pricing.
Switching in January vs Waiting Until October: Which Is Better for a High-Drug-Cost Enrollee?
Consider a concrete case. A 71-year-old on an Advantage plan in February 2026 discovers her rheumatologist has left the network and her biologic sits on a specialty tier with 33% coinsurance. She has two realistic options: use the January-through-March window now, or wait until the Annual Enrollment Period in the fall.
Switching in February means her new coverage begins March 1. She loses January and February under the old plan, then runs ten months under the new one. If she returns to Original Medicare plus a standalone Part D plan, her drug exposure is capped at $2,100 for the calendar year — and any spending already accumulated in January and February counts toward it, since the cap is a calendar-year figure tracked across plans within the year. Her Part D premium under CMS projections averages $34.50 monthly for a standalone plan, or $345 across ten months.
Waiting until October produces a different arithmetic. She absorbs all twelve months of specialty-tier coinsurance, though the $2,100 cap still stops the bleeding once she hits it. Her real risk is not the drug cost — it is the Medigap door. Waiting means she almost certainly falls outside any trial right, and by January 2027 she may face underwriting she cannot pass. The Part D plan selection and formulary comparison is solvable in either year. The Medigap application is not.
Verdict
Switch in the January 1–March 31 window if returning to Original Medicare is the goal and a trial right or guaranteed-issue event is available — the Medigap underwriting risk of waiting outweighs the modest cost of a partial-year plan change. Wait until the Annual Enrollment Period only if you intend to move between two Advantage plans, since the fall window permits multiple revisions and a January 1 effective date that avoids splitting the deductible year. For anyone whose primary complaint is network access rather than drug cost, act in the January window; provider directories are updated for the plan year and the one permitted change is enough to solve it.
What Most People Get Wrong About Switching
Five errors account for the overwhelming majority of expensive switching outcomes. Each has a specific corrective action.
Dropping Advantage without adding standalone Part D
Returning to Original Medicare removes your drug coverage, because it was bundled into the Advantage plan. The consequence is uncapped drug exposure plus a Part D late enrollment penalty that compounds permanently. Correct action: submit the standalone Part D election in the same transaction as the disenrollment, before March 31. Review the full enrollment deadlines and late penalty costs before you file anything.
Assuming the January window allows entry into Advantage
It does not. Someone on Original Medicare who submits an Advantage application in February will have it rejected. The consequence is a wasted month and a false sense that coverage is in place. Correct action: treat January through March as an exit-only window and plan Advantage entry for the fall.
Believing the switch takes effect immediately
Changes made in the January window begin the first day of the following month, not the day of submission. A March 29 election starts April 1. The consequence is a gap in expected coverage for scheduled procedures. Correct action: submit early in the month you want coverage to begin the month after.
Comparing plans on premium alone
A $0-premium Advantage plan and a $60 plan can differ by thousands in maximum out-of-pocket exposure, specialty coinsurance, and prior authorization burden. Correct action: model total annual cost, not monthly premium — the framework in comparing Advantage plans beyond premium handles this systematically.
Ignoring employer or retiree coverage interactions
Dropping an employer-sponsored retiree plan to switch is frequently irreversible; many plan sponsors will not readmit you. Correct action: obtain written confirmation of reinstatement rights before disenrolling, and check the mechanics of Medicare coordination with employer coverage first.
Who Should Actually Switch — and Who Should Not
Switching is worth the friction under a narrow set of conditions. It is not a default annual ritual.
Switch if any of the following is true. Your physician or hospital system left the network, and the replacement is materially worse — network churn is the single most common legitimate trigger. Your prescription moved to a higher formulary tier or off formulary entirely, which the Annual Notice of Change discloses each fall. Your health has declined and Original Medicare’s unrestricted provider access plus a supplement now outperforms a narrow network, a calculation examined in Advantage vs Original Medicare for chronic conditions. You are inside a 12-month trial right and have not yet used it. Or you have moved out of your plan’s service area, which triggers a Special Enrollment Period independent of the calendar.
Do not switch when the motivation is a marginal premium difference, a supplemental benefit you will rarely use, or a mailer promising dental and vision coverage with a low annual maximum. Those benefits are real but small, and the exclusions are broader than most enrollees expect — see dental, vision, and hearing exclusions. Do not switch out of Advantage into Original Medicare without a supplement unless you have significant liquid savings, because the $1,736 Part A deductible resets with each new benefit period, with no annual ceiling. The tradeoffs are quantified in the Medigap vs Medicare Advantage annual cost comparison.
One additional case deserves flagging. Beneficiaries whose income crossed the $109,000 single or $218,000 joint threshold two years ago will see IRMAA applied regardless of which plan they select, and a life-changing event may support a reduction request under the IRMAA surcharge rules and reduction requests. Switching plans does nothing to address it.
Frequently Asked Questions
Can I change my mind twice during the January window?
No. The Medicare Advantage Open Enrollment Period permits exactly one change between January 1 and March 31. This differs from the Annual Enrollment Period, where the last election submitted before December 7 controls and earlier elections are superseded. If you switch Advantage plans in January and dislike the new one in February, you generally wait until October 15 unless a Special Enrollment Period applies.
Does my Part D spending reset when I switch plans mid-year?
Your true out-of-pocket spending toward the $2,100 annual cap carries across plans within the same calendar year, because the cap is defined by statute on a calendar-year basis. Your deductible treatment can differ by plan, though; the maximum Part D deductible is $615 in 2026 and many plans now charge the full amount. Confirm accumulator transfer directly with the receiving plan before the effective date.
If I return to Original Medicare in February, when can I buy Medigap?
Guaranteed-issue rights generally run 63 days from the date your Advantage coverage ends, and applications may be submitted as early as 60 days before that date. If your Advantage coverage ends February 28, apply within that window rather than waiting. Outside a guaranteed-issue event, most states allow insurers to underwrite and decline your application entirely.
Does switching plans change my Part B premium?
No. The standard Part B premium of $202.90 monthly in 2026 is set by CMS and is owed regardless of whether you carry Original Medicare, Medigap, or a Medicare Advantage plan. Some Advantage plans offer a Part B premium giveback that reduces the amount withheld from Social Security, but the underlying obligation is unchanged. IRMAA surcharges, ranging from $284.10 to $689.90 monthly, are similarly plan-independent.
How We Researched This Article
All 2026 cost figures in this analysis were drawn from primary federal sources and verified before publication. Part A and Part B premiums, deductibles, and coinsurance amounts come from the Centers for Medicare & Medicaid Services announcement of November 14, 2025, and the corresponding notice published in the Federal Register on Part B actuarial rates and premiums. Income-related monthly adjustment amount tiers and thresholds were confirmed against the Railroad Retirement Board summary of 2026 Medicare premiums, which republishes CMS determinations for railroad annuitants under identical statutory formulas.
Part D parameters — the $615 maximum deductible and the $2,100 annual out-of-pocket cap — derive from CMS final parameters implementing the Inflation Reduction Act benefit redesign. Projected average premiums for standalone drug plans and Advantage drug coverage are CMS projections, not measured amounts, and actual premiums vary by county and carrier. Enrollment period mechanics, including the one-change limitation and first-of-following-month effective dates, were verified against CMS enrollment guidance and the Medicare Rights Center summary of the Advantage and General Enrollment Periods. Trial right and guaranteed-issue provisions were checked against CMS National Training Program materials.
Limitations are material and worth stating plainly. Medigap underwriting practices are regulated at the state level, and several states — including New York, Connecticut, Maine, and Massachusetts — impose continuous or annual guaranteed-issue requirements that override the federal baseline described here. This analysis reflects the federal floor, not any state’s enhanced protections. Advantage plan networks, formularies, and out-of-pocket maximums are set by individual carriers and change annually; no figure in this article should be treated as representative of a specific plan. The February switching scenario is modeled, not measured — it applies verified federal parameters to a hypothetical enrollee to illustrate the arithmetic, and individual results will differ based on drug list, county, and carrier. Research last conducted July 2026.
All figures were verified against named primary sources before publication.